Philadelphia, PA – Plexus Ventures is pleased to announce that its client, Fujifilm Kyowa Kirin Biologics (FKB), has confirmed that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application for FKB327 (adalimumab biosimilar)....

Tokyo, Japan - Plexus Ventures is pleased to announce the successful completion of an out-licensing project on behalf of Cynata Therapeutics Ltd. Plexus provided professional services to Cynata in the out-licensing of its lead product, CYP-001, to FUJIFILM...

London, United Kingdom - Plexus Ventures is pleased to announce it served as advisor to Celon Pharma SA and Polfarmex SA in the out-licensing of Salmex® Orbicel® (fluticasone/salmeterol), a generic version of GSK’s Advair® Diskus®, to an undisclosed company for...

Philadelphia, Pennsylvania - Plexus Ventures is pleased to announce it served as advisor to Mabion S.A. in the out-licensing of Mabion CD20 (Rituximab Biosimilar) European rights to Mylan Ireland Limited. Michael O’Sullivan, Managing Partner of Plexus Ventures’ London...

Philadelphia, Pennsylvania - Plexus Ventures announces the successful completion of a recent out-licensing project on behalf of Celon Pharma. Additional details regarding the transaction, taken from Glenmark’s October 23, 2015 press release are included below:...

Philadelphia, PA - Plexus Ventures LLC, a leading global pharmaceutical business development consultancy, announced today that Gabriele Tundo has joined the firm as an Associate. Gabriele Tundo, a native Italian, joined Plexus Ventures in October, 2015 and is based in...

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the appointment of Theresa Covert Walker as Vice President based in the Pensacola area.  Theresa joins Plexus after a 27-year career at Merck & Co., bringing significant executive, business...

Earlier this year, Healthware Group and Plexus Ventures formed an alliance to structure deals for the pharmaceutical industry in the development and commercialization of Digital Therapeutic (DTx) products. Given the increased attention...